Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04798651
Recruiting Not applicable

Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis

NCT04798651 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Bordeaux
Phase
Not applicable
Started
2021-09-30
Last updated
2026-02-03

Condition(s) studied

Multiple SclerosisClinically Isolated Syndrome

Investigational drug(s) / intervention(s)

blood sample →cerebro-spinal fluid

blood sample: 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

cerebro-spinal fluid: 1 ml of cerebro-spinal fluid

Study summary

The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * male or female subjects ; * Age ≥ 18 years; * subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome; * patients for which a blood draw and / or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose; * affiliated to an health insurance system; * and who agree to participate in the study. Exclusion Criteria: * Pregnant or breastfeeding women, * patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)

Primary outcome measure(s)

  • Functional and phenotypical characterization of the blood and CSF lymphocytes in MS and CIS patients. — At inclusion (day 0)

Trial sites (1)

FacilityCityRegionStatus
CHU de Bordeaux - service de neurologie Bordeaux France Recruiting

More University Hospital, Bordeaux trials in France

Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN) Recruiting
A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression Recruiting
Parkinsonism-Related Oscillations in the Cortico-Basal Ganglia-Thalamic Network During Movement: Beyond the Frequency Range Recruiting
Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction Recruiting
Performance of Lung MRI Combined to Synthetic CT in the Follow-up of Lung Nodules Recruiting

Other trials for the same condition

TWEAK, a New Biomarker for Predicting Inflammatory Relapses in Multiple Sclerosis Recruiting
Switch to Ofatumumab and Level of Immunoglobulins Starting soon
Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis Recruiting
Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET) Recruiting
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04798651 on ClinicalTrials.gov ↗ ← All trials in France